Table 1.
(±SE,g) | ||||
---|---|---|---|---|
−48 hrs | −24 hrs | 0 hr | 24 hrs | |
Con | 0.272±0.069 | 0.076±0.046 | 0.011±0.001 | 0.024±0.005 |
O-con | 0.379±0.098 | 0.135±0.099 | 0.020±0.014 | 0.027±0.003 |
G-con | 0.196±0.082 | 0.113±0.078 | 0.010±0.002 | 0.017±0.004 |
Model | 0.364±0.170 | 0.072±0.032 | 0.022±0.013 | 0.547±0.119aaa |
O-treated | 0.485±0.123 | 0.171±0.033 | 0.025±0.009 | 0.195±0.084b |
G-treated | 0.503±0.101 | 0.134±0.027 | 0.034±0.007 | 0.210±0.098b |
Notes: aaaP<0.001, compared with Con, bP<0.05, compared with model. Cisplatin (6 mg/kg (weight), i.p.) was administered at t=0.
Abbreviations: Con, the normal control group; O-Con, the rats treated with ondansetron; G-con, the rats treated with [6]-gingerol; Model, the rats injected intraperitoneally with cisplatin; O-treated, the ondansetron-treated model group; G-treated, the [6]-gingerol-treated model group.